| Identification | Back Directory | [Name]
Ro 41-5253 | [CAS]
144092-31-9 | [Synonyms]
Ro 41-5253
Ro 41-5253 >=98% (HPLC)
4-[2-(7-Heptoxy-4,4-dimethyl-1,1-dioxo-2,3-dihydrothiochromen-6-yl)4-(2-(7-(Heptyloxy)-3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)-1-propenyl)-Benzoic acid, S,S-dioxide
4-[(1E)-2-[7-(Heptyloxy)-3,4-dihydro-4,4-dimethyl-1,1-dioxido-2H-1-benzothiopyran-6-yl]-1-propen-1-yl]-benzoic acid
Benzoic acid, 4-[(1E)-2-[7-(heptyloxy)-3,4-dihydro-4,4-dimethyl-1,1-dioxido-2H-1-benzothiopyran-6-yl]-1-propen-1-yl]- | [Molecular Formula]
C28H36O5S | [MDL Number]
MFCD00926134 | [MOL File]
144092-31-9.mol | [Molecular Weight]
484.65 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C | [solubility ]
DMSO: soluble20mg/mL, clear | [form ]
powder | [color ]
white to beige | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. |
| Hazard Information | Back Directory | [Description]
Ro 41-5253 (144092-31-9) is a selective RARα antagonist.1?Binds RARα without inducing transcription or influencing RAR/RXR heterodimerization and DNA binding.2?Ro 415253 inhibits proliferation and induces apoptosis in a variety of cell lines/types. Cell Permeable. | [Uses]
Ro 415253 is a retinoic acid receptor antagonists, a promising starting point for antimetastatic therapies. | [Definition]
ChEBI: A thiochromane that is 3,4-dihydro-2H-1-benzothiopyran S,S-dioxide in which the hydrogens at position 4 are both replaced by methyl groups, the hydrogens at position 7 is replaced by a heptyloxy group, w
ile the hydrogen at position 6 is replaced by a 1-phenylprop-1-en-2-yl group, the phenyl group of which is substituted at the para position by a carboxy group. It is a selective antagonist for retinoic acid receptor alpha. | [in vivo]
Ro 41-5253 (oral gavage, 10-600 mg/kg, once a week, 4 weeks) can reduce tumor volume in female athymic Balb/mice transplanted with MCF-7 cell line[2].
| Animal Model: | Six-week-old female athymic Balb/mice transplanted with MCF-7 cell line[2] | | Dosage: | 10, 30, 100, 300 and 600 mg/kg | | Administration: | Oral gavage; once a week; 4 weeks | | Result: | Resulted in a reduction in tumor volume at doses of 10, 30 and 100 mg/kg with no toxic side effects. |
| [storage]
Store at -20°C | [References]
1) Apfel?et al. (1992),?A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects; Proc. Natl. Acad. Sci. USA,?89?7129
2) Toma?et al. (1998),?RARα antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines; Int. J. Cancer,?78?86 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|